(EMR) Emerson Electric - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2910111044

Valves, Instruments, Actuators, Controllers, Tools

EMR EPS (Earnings per Share)

EPS (Earnings per Share) of EMR over the last years for every Quarter: "2020-09": 1.1, "2020-12": 0.83, "2021-03": 0.97, "2021-06": 1.09, "2021-09": 1.21, "2021-12": 1.05, "2022-03": 1.29, "2022-06": 1.38, "2022-09": 1.53, "2022-12": 0.78, "2023-03": 1.09, "2023-06": 1.29, "2023-09": 1.29, "2023-12": 1.22, "2024-03": 1.36, "2024-06": 1.43, "2024-09": 1.48, "2024-12": 1.38, "2025-03": 1.48, "2025-06": 1.04, "2025-09": 1.62,

EMR Revenue

Revenue of EMR over the last years for every Quarter: 2020-09: 4558, 2020-12: 4161, 2021-03: 4431, 2021-06: 4697, 2021-09: 4947, 2021-12: 3156, 2022-03: 3291, 2022-06: 3465, 2022-09: 5360, 2022-12: 3373, 2023-03: 3756, 2023-06: 3946, 2023-09: 4090, 2023-12: 4117, 2024-03: 4376, 2024-06: 4380, 2024-09: 4619, 2024-12: 4175, 2025-03: 4432, 2025-06: 4553, 2025-09: 4855,
Risk via 10d forecast
Volatility 30.1%
Value at Risk 5%th 43.9%
Reward
Sharpe Ratio 0.07
Alpha Jensen -14.86
Character
Hurst Exponent 0.574
Beta 1.250
Drawdowns 3y
Max DD 29.62%
Mean DD 7.67%

Description: EMR Emerson Electric September 26, 2025

Emerson Electric Co. (NYSE: EMR) is a diversified technology and software firm headquartered in St. Louis, Missouri, with operations spanning the Americas, Asia, the Middle East, Africa, and Europe.

The business is organized into six segments: Final Control; Measurement & Analytical; Discrete Automation; Safety & Productivity; Control Systems & Software; and Test & Measurement. Across these segments the company supplies a broad portfolio that includes control, isolation, shut-off, pressure-relief, and safety valves, as well as actuators and regulators for process and hybrid industries.

Its instrumentation line measures key physical properties of liquids and gases-pressure, temperature, level, flow, acoustics, corrosion, pH, conductivity, water quality, toxic gases, and flame detection-while its valve and pneumatic offerings cover solenoid and pneumatic valves, position indicators, cylinders, air-preparation equipment, and electric linear-motion solutions.

Emerson also delivers automation hardware such as programmable control systems, electrical distribution gear, and materials-joining technologies, complemented by a professional-tool segment that serves both contractors and homeowners with pipe-working, hydraulic, and electrical tools.

On the software side, the firm provides control-system architectures, safety-instrumented systems, SCADA platforms, digital-twin and asset-performance-management tools, and cybersecurity solutions. Its test-and-measurement business offers software-connected automated systems, while its asset-optimization suite leverages decades of modeling, simulation, and optimization to improve industrial performance.

Key recent metrics: FY 2023 revenue reached $20.5 billion, operating margin held near 14 percent, and free cash flow topped $2.1 billion; the dividend yield is roughly 2.5 percent with a five-year payout growth rate of about 6 percent. The Discrete Automation and Control Systems & Software segments have been the primary drivers of double-digit top-line growth, reflecting robust capital-expenditure cycles in oil-&-gas, chemicals, and the expanding renewable-energy infrastructure.

Sector-level trends that underpin Emerson’s outlook include accelerating industrial automation adoption, heightened focus on energy-transition assets that require advanced process control, and increasing regulatory pressure for safety-instrumented systems-factors that collectively boost demand for Emerson’s integrated hardware-software solutions.

For a deeper dive into Emerson’s valuation metrics and scenario analysis, the ValueRay platform offers a transparent, data-driven view worth checking out.

EMR Stock Overview

Market Cap in USD 72,877m
Sub-Industry Electrical Components & Equipment
IPO / Inception 1972-06-01
Return 12m vs S&P 500 -11.9%
Analyst Rating 4.27 of 5

EMR Dividends

Dividend Yield 1.59%
Yield on Cost 5y 2.99%
Yield CAGR 5y 1.19%
Payout Consistency 100.0%
Payout Ratio 38.7%

EMR Growth Ratios

CAGR 12.91%
CAGR/Max DD Calmar Ratio 0.44
CAGR/Mean DD Pain Ratio 1.68
Current Volume 2346.9k
Average Volume 2509.1k

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (2.29b TTM) > 0 and > 6% of Revenue (6% = 1.08b TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 3.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -9.21% (prev 25.44%; Δ -34.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.07 (>3.0%) and CFO 3.17b > Net Income 2.29b (YES >=105%, WARN >=100%)
Net Debt (14.87b) to EBITDA (4.95b) ratio: 3.01 <= 3.0 (WARN <= 3.5)
Current Ratio 0.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (565.5m) change vs 12m ago -1.55% (target <= -2.0% for YES)
Gross Margin 52.84% (prev 50.79%; Δ 2.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 41.53% (prev 39.53%; Δ 1.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 9.15 (EBITDA TTM 4.95b / Interest Expense TTM 356.0m) >= 6 (WARN >= 3)

Altman Z'' 3.34

(A) -0.04 = (Total Current Assets 9.07b - Total Current Liabilities 10.73b) / Total Assets 42.52b
(B) 0.95 = Retained Earnings (Balance) 40.27b / Total Assets 42.52b
warn (B) unusual magnitude: 0.95 — check mapping/units
(C) 0.08 = EBIT TTM 3.26b / Avg Total Assets 43.38b
(D) 0.0 = Book Value of Equity 0.0 / Total Liabilities 22.63b
Total Rating: 3.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.03

1. Piotroski 7.50pt = 2.50
2. FCF Yield 3.12% = 1.56
3. FCF Margin 15.22% = 3.80
4. Debt/Equity 0.75 = 2.23
5. Debt/Ebitda 3.01 = -1.77
6. ROIC - WACC (= -0.74)% = -0.92
7. RoE 11.29% = 0.94
8. Rev. Trend 88.86% = 6.66
9. EPS Trend 60.54% = 3.03

What is the price of EMR shares?

As of November 14, 2025, the stock is trading at USD 128.46 with a total of 2,346,900 shares traded.
Over the past week, the price has changed by -2.30%, over one month by +0.22%, over three months by -4.47% and over the past year by +0.35%.

Is Emerson Electric a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Emerson Electric (NYSE:EMR) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.03 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EMR is around 131.14 USD . This means that EMR is currently overvalued and has a potential downside of 2.09%.

Is EMR a buy, sell or hold?

Emerson Electric has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy EMR.
  • Strong Buy: 19
  • Buy: 3
  • Hold: 6
  • Sell: 1
  • Strong Sell: 1

What are the forecasts/targets for the EMR price?

Issuer Target Up/Down from current
Wallstreet Target Price 151 17.5%
Analysts Target Price 151 17.5%
ValueRay Target Price 146.7 14.2%

EMR Fundamental Data Overview November 10, 2025

Market Cap USD = 72.88b (72.88b USD * 1.0 USD.USD)
P/E Trailing = 32.1315
P/E Forward = 20.3252
P/S = 4.0451
P/B = 3.7685
P/EG = 1.4016
Beta = 1.25
Revenue TTM = 18.02b USD
EBIT TTM = 3.26b USD
EBITDA TTM = 4.95b USD
Long Term Debt = 8.28b USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.10b USD (from shortTermDebt, two quarters ago)
Debt = 14.87b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 14.87b USD (using Total Debt 14.87b, CCE unavailable)
Enterprise Value = 87.75b USD (72.88b + Debt 14.87b - (null CCE))
Interest Coverage Ratio = 9.15 (Ebit TTM 3.26b / Interest Expense TTM 356.0m)
FCF Yield = 3.12% (FCF TTM 2.74b / Enterprise Value 87.75b)
FCF Margin = 15.22% (FCF TTM 2.74b / Revenue TTM 18.02b)
Net Margin = 12.73% (Net Income TTM 2.29b / Revenue TTM 18.02b)
Gross Margin = 52.84% ((Revenue TTM 18.02b - Cost of Revenue TTM 8.50b) / Revenue TTM)
Gross Margin QoQ = 51.91% (prev 52.56%)
Tobins Q-Ratio = 2.06 (Enterprise Value 87.75b / Total Assets 42.52b)
Interest Expense / Debt = 0.62% (Interest Expense 92.0m / Debt 14.87b)
Taxrate = 20.10% (160.0m / 796.0m)
NOPAT = 2.60b (EBIT 3.26b * (1 - 20.10%))
Current Ratio = 0.85 (Total Current Assets 9.07b / Total Current Liabilities 10.73b)
Debt / Equity = 0.75 (Debt 14.87b / totalStockholderEquity, two quarters ago 19.87b)
Debt / EBITDA = 3.01 (Net Debt 14.87b / EBITDA 4.95b)
Debt / FCF = 5.42 (Net Debt 14.87b / FCF TTM 2.74b)
Total Stockholder Equity = 20.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.39% (Net Income 2.29b / Total Assets 42.52b)
RoE = 11.29% (Net Income TTM 2.29b / Total Stockholder Equity 20.31b)
RoCE = 11.40% (EBIT 3.26b / Capital Employed (Equity 20.31b + L.T.Debt 8.28b))
RoIC = 8.16% (NOPAT 2.60b / Invested Capital 31.89b)
WACC = 8.90% (E(72.88b)/V(87.75b) * Re(10.62%) + D(14.87b)/V(87.75b) * Rd(0.62%) * (1-Tc(0.20)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.68%
[DCF Debug] Terminal Value 67.07% ; FCFE base≈2.12b ; Y1≈1.88b ; Y5≈1.57b
Fair Price DCF = 34.03 (DCF Value 19.15b / Shares Outstanding 562.8m; 5y FCF grow -13.79% → 3.0% )
EPS Correlation: 60.54 | EPS CAGR: 30.44% | SUE: 0.0 | # QB: 0
Revenue Correlation: 88.86 | Revenue CAGR: 14.16% | SUE: -0.47 | # QB: 0

Additional Sources for EMR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle